Is the FTC about to force Roche to di­vest a key he­mo­phil­ia pro­gram be­fore green-light­ing Spark buy­out?

Mizuho Se­cu­ri­ties an­a­lyst Difei Yang has been con­sult­ing with the FTC ex­perts at Allen & Overy over Roche’s long-de­layed $4.3 bil­lion Spark Ther­a­peu­tics buy­out. And …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER